Take the next step with Precise Tumor

Request more information or explore ordering options to bring Precise Tumor testing to your practice.

Request information

Take the next step with Precise Tumor

Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.

Precise Tumor Molecular Profile Test

A pan-cancer solid tumor comprehensive genomic profiling test

Precise Tumor  simplifies patient care for clinicians by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.

Precise Tumor Molecular Profile Test

A pan-cancer solid tumor comprehensive genomic profiling test

Precise Tumor  simplifies patient care for clinicians by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.

Somatic testing with Precise Tumor provides you with clarity and confidence

Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors. This hybrid-capture DNA- and RNA-based test detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), splice variants and fusions in solid tumors. Test specifications can be found in the detailed sales aid below.

By using tumor testing procedures that you are familiar with in an innovative and comprehensive way, Precise Tumor testing will allow you to save time, gain confidence, and arm yourself with the information you need to help your patients. 

Use next-generation genomic profiling to guide cancer treatment decisions

Precise Tumor is validated for all solid tumor types and includes sequencing of over 500 genes identified as relevant to cancer treatment, as well as testing of important immunotherapy (IO) biomarkers to provide a comprehensive picture for you to formulate a treatment plan with your patients.

Use next-generation genomic profiling to guide cancer 
treatment decisions

Precise Tumor features

  • Actionable

    500+ solid tumor-related genes with broad coverage of key guidelines and clinical trials for multiple solid tumor types. (View full biomarker list)

    Key Selected Biomarkers:

    • Microsatellite Instability (MSI)
    • Tumor Mutational Burden (TMB)
    • Programmed Death-Ligand 1 (PD-L1), if requested.
  • Clinically Validated & Comprehensive

    Provides genomic coverage necessary for accurate selection of FDA-approved targeted and IO therapies, while also evaluating many genes relevant to early phase drug development efforts that may have future clinical applications in all solid tumors.1

  • Accurate

    Validated to 98.91% Analytical Sensitivity and >99.99% Analytical Specificity with targeted exome sequencing with full coverage of all exons. Accurately measures TMB, microsatellite instability, SNVs, indels, copy-number/structural variation and gene fusions when compared to WGS and orthogonal technologies.2

  • Cutting-Edge Technologies

    Fusions and splice variants assessed via RNA analysis, which may detect more actionable fusions and splice variants, as compared to DNA tests only.3-6

Precise Tumor detects clinically relevant DNA & RNA variants for multiple solid-tumor cancer types

Content for Precise Tumor includes key guideline biomarkers for multiple cancer types, plus current and emerging pan-cancer biomarkers, to provide you with a comprehensive picture for formulating treatment plans.

Some key cancer-specific biomarkers include:

Breast cancer biomarkers
Colon cancer biomarkers
Lung cancer biomarkers
Ovarian cancer biomarkers
Pancreatic cancer biomarkers
Pan-cancer biomarkers
Endometrial cancer biomarkers
Prostate cancer biomarkers

How to test with Precise Tumor

Fill out a test request form in the Myriad Genetics provider portal

Fill out a test request form in the Myriad Genetics provider portal

Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing

Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing

Results will be reported in the provider portal as they become available

Results will be reported in the provider portal as they become available

One simple order. Comprehensive results.

With Precise™ Oncology Solutions, you can receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including Precise Tumor, in one single ordering experience, getting clear, fast answers for your patients.

What to expect with every Precise Tumor test

Actionable

Precise Tumor simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.

Accurate

Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.

Clinical resources

References:
  1. Conroy et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021 Dec 2;16(12):e0260089. 
  2. Pestinger et al. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Mol Diagn Ther. 2020 Jun;24(3):339-349. 
  3. Benayed et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration as detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. 2019 August 01; 25(15):4712-4722. 
  4. Wong et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusions Cancer. Pathol Oncol Res. 2020 Jul; 26(3): 1385-1399. 
  5. Yang et al. A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clin Cancer Res. 2020 Dec 3. 
  6. Radonic et al. RET FISH Analysis is a sensitive by highly unspecific method for RET fusions in lung cancer. J Thora Oncol. 2021 Feb 12.